Search Results - "Biggar, Erin"

Randomized, double-blind, placebo-controlled phase 3 study of ibrutinib plus rituximab in patients with previously untreated marginal zone lymphoma (MZL) by Noy, Ariela, Hughes, Stephanie, Biggar, Erin, Bogdan, Matthew

“…Abstract only TPS7576 Background: First-line treatment options for patients with MZL include single-agent immunotherapy, chemotherapy, or chemoimmunotherapy…”
Get full text

A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma by Gurumurthi, Ashwath, Bantilan, Kurt S, Hamlin, Paul A, Kumar, Anita, Matasar, Matthew, Zhu, Menglei, Joseph, Ashlee, Castro, Ali, Biggar, Erin, Salles, Gilles, Zelenetz, Andrew D, von Keudell, Gottfried

Get full text

Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL) by Sermer, David J., Vardhana, Santosha, Biggar, Erin, Moskowitz, Alison J., Joffe, Erel, Khan, Niloufer, Straus, David J., Kumar, Anita, Zelenetz, Andrew D., Horwitz, Steven M., Noy, Ariela, Batlevi, Connie Lee, Hamilton, Audrey, Owens, Colette, Matasar, Matthew J., Palomba, M. Lia, Lee, Christina Y., Falchi, Lorenzo, Johnson, William T., Schoder, Heiko, Dogan, Ahmet, Bunyaviroch, Tira, Seshan, Venkatraman, Salles, Gilles, Younes, Anas, von Keudell, Gottfried

“…Introduction Histone deacetylase (HDAC) inhibitors have single agent activity in various types of lymphoma. They restore antigen-specific immune recognition in…”
Get full text

Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL) by Sermer, David J., Vardhana, Santosha Adipudi, Ames, Ashley, Biggar, Erin, Moskowitz, Alison J., Batlevi, Connie Lee, Caron, Philip, Hamilton, Audrey M., Moskowitz, Craig H., Matasar, Matthew J., Zelenetz, Andrew David, Horwitz, Steven M., Von Keudell, Gottfried, Yahalom, Joachim, Rademaker, Jurgen, Dogan, Ahmet, Seshan, Venkatraman E., Younes, Anas

“…Abstract only e20018 Background: Histone deacetylase (HDAC) inhibitors have single agent activity in various types of lymphoma. They have been shown to restore…”
Get full text

A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma by Qualls, David, Lam, Hiu Ying, Whiting, Karissa, Kumar, Anita, Matasar, Matthew, Owens, Colette, Nichols, Chelsea, Espeleta, James A, Qiu, Annie, Subzwari, Sarima, Biggar, Erin, Seshan, Venkatraman, Salles, Gilles, Younes, Anas, Batlevi, Connie

Get full text